| Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 173 | 2022 |
| Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver E Kaya, Y Yilmaz Journal of clinical and translational hepatology 10 (2), 329, 2022 | 81 | 2022 |
| Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. E Kaya, A Bakir, HT Kani, CO Demirtas, C Keklikkiran, Y Yilmaz Gut and Liver, 2019 | 57 | 2019 |
| Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients PH Varol, E Kaya, E Alphan, Y Yilmaz European journal of gastroenterology & hepatology 32 (10), 1352-1357, 2020 | 51 | 2020 |
| Non-alcoholic fatty liver disease: A growing public health problem in Turkey. E Kaya, Y Yilmaz Turk J Gastroenterol, 2019 | 50 | 2019 |
| Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index … F Eren, E Kaya, Y Yilmaz European journal of gastroenterology & hepatology 34 (1), 98-103, 2022 | 49 | 2022 |
| Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease T Alkayyali, L Qutranji, E Kaya, A Bakir, Y Yilmaz Acta diabetologica 57, 613-618, 2020 | 49 | 2020 |
| Characterization of patients with biopsy-proven non-alcoholic fatty liver disease and normal aminotransferase levels C Ulasoglu, FY Enc, E Kaya, Y Yilmaz J Gastrointestin Liver Dis 28 (4), 427-431, 2019 | 37 | 2019 |
| The utility of noninvasive scores in non-alcoholic fatty liver disease patients with normal and elevated serum transaminases E Kaya, A Bakir, F Eren, Y Yilmaz Hepatology Forum 1 (1), 8, 2020 | 34 | 2020 |
| The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver … F Jafarov, E Kaya, A Bakir, F Eren, Y Yilmaz European journal of gastroenterology & hepatology 32 (5), 642-649, 2020 | 33 | 2020 |
| Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience. Y Yilmaz, HT Kani, CO Demirtas, E Kaya, AF Sapmaz, L Quatranji, ... Turk J Gastroenterol, 2019 | 33 | 2019 |
| Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter E Kaya, D Demir, YO Alahdab, Y Yilmaz European journal of gastroenterology & hepatology 28 (11), 1264-1267, 2016 | 29 | 2016 |
| The prevalence of metabolic-associated fatty liver disease in the Turkish population: A multicenter study Y Yilmaz, N Yilmaz, F Ates, F Karakaya, H Gokcan, E Kaya, G Adali, ... Hepatology Forum 2 (2), 37, 2021 | 27 | 2021 |
| Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever S Trabulus, M Korkmaz, E Kaya, N Seyahi Clinical Transplantation 32 (8), e13345, 2018 | 26 | 2018 |
| Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease E Kaya, Y Yilmaz Therapeutic Advances in Endocrinology and Metabolism 13, 20420188221139650, 2022 | 17 | 2022 |
| Association of nutritional assessment by phase angle with mortality in kidney transplant patients in an 8-year follow-up E Kaya, A Bakir, YK Koseoglu, M Velidedeoglu, S Trabulus, N Seyahi Progress in Transplantation 29 (4), 321-326, 2019 | 16 | 2019 |
| A review of the epidemiology, pathophysiology, and efficacy of anti-diabetic drugs used in the treatment of nonalcoholic fatty liver disease PP Manka, E Kaya, A Canbay, WK Syn Digestive diseases and sciences 66 (11), 3676-3688, 2021 | 13 | 2021 |
| Prevention of hepatocellular carcinoma and monitoring of high-risk patients E Kaya, GD Mazzolini, Y Yilmaz, A Canbay Hepatology Forum 3 (1), 33, 2022 | 11 | 2022 |
| Türkiye’de ve dünyada nonalkolik yağlı karaciğer hastalığı epidemiyolojisi E Kaya, Y Yılmaz Türkiye Klinikleri (Ortadoğu Reklam Tanıtım Yayıncılık), 2019 | 11 | 2019 |
| Marmara University medical students’ perception on sexual violence against women and induced abortion in Turkey NE Lüleci, E Kaya, E Aslan, ES Şenkal, ZN Çiçek Balkan medical journal 33 (2), 173-180, 2016 | 11 | 2016 |
